MARKET

JNCE

JNCE

Jounce
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.92
-0.44
-5.26%
Closed 19:04 05/06 EDT
OPEN
8.26
PREV CLOSE
8.36
HIGH
8.42
LOW
7.76
VOLUME
477.00K
TURNOVER
--
52 WEEK HIGH
14.84
52 WEEK LOW
4.300
MARKET CAP
405.57M
P/E (TTM)
-5.5443
1D
5D
1M
3M
1Y
5Y
Jounce Therapeutics (JNCE) Receives a Buy from Robert W. Baird
In a report issued on May 4, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Jounce Therapeutics (JNCE), with a price target of $15.00.
SmarterAnalyst · 1d ago
BRIEF-Jounce Therapeutics Files For Mixed Shelf Of Up To $250 Mln– SEC Filing
reuters.com · 2d ago
10-Q: JOUNCE THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 2d ago
DJ Jounce Therapeutics, Inc. CEO Rich Murray on Q1 2021 Results -- Earnings Call Transcript >JNCE
Dow Jones · 2d ago
Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -56.76% and -97.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3d ago
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3)
Benzinga · 3d ago
BRIEF-Jounce Therapeutics Reports First Quarter 2021 Financial Results
reuters.com · 3d ago
Jounce Therapeutics Q1 EPS $(0.58) Misses $(0.41) Estimate
Jounce Therapeutics (NASDAQ:JNCE) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.41) by 41.46 percent. This is a 25.64 percent increase over losses of $(0.78) per share
Benzinga · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JNCE. Analyze the recent business situations of Jounce through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JNCE stock price target is 16.00 with a high estimate of 20.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 149
Institutional Holdings: 30.62M
% Owned: 59.80%
Shares Outstanding: 51.21M
TypeInstitutionsShares
Increased
25
3.77M
New
18
1.61M
Decreased
41
2.36M
Sold Out
15
684.43K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.09%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Non-Executive Chairman/Independent Director
Perry Karsen
President/Chief Executive Officer/Director
Richard Murray
Chief Financial Officer/Treasurer
Kimberlee Drapkin
Other
Hugh Cole
Other
Elizabeth Trehu
Secretary
Jacqui Sandell
Director
Luisa Salter-Cid
Independent Director
Luis Diaz
Independent Director
Barbara Duncan
Independent Director
J. Duncan Higgons
Independent Director
Robert Iannone
Independent Director
Robert Kamen
Independent Director
Cary Pfeffer
Independent Director
Robert Tepper
No Data
About JNCE
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

Webull offers kinds of Jounce Therapeutics Inc stock information, including NASDAQ:JNCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JNCE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JNCE stock methods without spending real money on the virtual paper trading platform.